search
Back to results

Evaluation and Validation of Management Strategy for Conductive Disorders After TAVR (EVATAVI) (EVATAVI)

Primary Purpose

Valvular Heart Disease

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Use of flowchart
Sponsored by
University Hospital, Montpellier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Valvular Heart Disease focused on measuring Aortic Valve,, Aortic Valve Stenosis,, Heart Valve Prosthesis Implantation,, Transcatheter Aortic Valve Replacement,, Telemetry,, Intensive care

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Any patient who benefits from femoral TAVR regardless of the type of valve.
  • Age ≥ 18 years old.

Exclusion Criteria:

  • Patients who require CICU monitoring for a reason other than conduction disorders
  • Patients with pacemaker or defibrillator
  • Pregnant or breastfeeding women
  • Patient refusing or unable to give consent: patient under guardianship or curator, mentally retarded, dementia, language barrier
  • Patient not affiliated with an SS scheme
  • Patient under judicial protection

Sites / Locations

  • University HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Management of conductive disorders after TAVR

Arm Description

Evaluation of efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR

Outcomes

Primary Outcome Measures

Occurrence of a serious conductive disorder
Occurrence of a serious conductive disorder (one among the following : syncope, malaise, sudden death, heart failure) outside the CICU (whether the patient was there admitted initially or not)
Occurrence of a serious conductive disorder requiring specific management
Occurrence of a serious conductive disorder requiring specific management (one among the following : drug treatment, need for a transient or permanent pacemaker), outside the CICU (whether the patient was there admitted initially or not)

Secondary Outcome Measures

Incidence and type of conductive disorders requiring transfer to CICU (cardiac intensive care unit)
Pourcentage of Pacemaker implantation
Time of onset of conductive disorders requiring a pacemaker (immediate, hospital phase, after discharge from hospital)
Description of the evolution of conductive disorders that have not been the subject of pacemaker insertion (hospitalization)
Number of conductive disorders that lead to patient's rehospitalization
Description of the evolution of conductive disorders that have not been the subject of pacemaker insertion (death)
Number of conductive disorders that lead to patient's death
Death
Clinical status at one month (NYHA (New York Heart Association)
Death within the first month after TAVR
Duration of hospitalization in CICU
Duration of hospitalization in sector

Full Information

First Posted
June 2, 2022
Last Updated
March 6, 2023
Sponsor
University Hospital, Montpellier
search

1. Study Identification

Unique Protocol Identification Number
NCT05417464
Brief Title
Evaluation and Validation of Management Strategy for Conductive Disorders After TAVR (EVATAVI)
Acronym
EVATAVI
Official Title
Evaluation and Validation of a Monitoring, Screening and Management Strategy for Conductive Disorders After TAVR (EVATAVI)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 21, 2023 (Actual)
Primary Completion Date
February 21, 2024 (Anticipated)
Study Completion Date
March 21, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Considering decrease of major complications and improvement of procedural results, conductive disorders currently remain the main issue after TAVR (Transcatheter aortic valve replacement). While pacemaker implantation rate was about 10-15%, new onset LBBB (Left bundle branch block) was observed in 30 % of patients after TAVR but resolved at discharge in the majority of them, with less than 20% progressed to complete AV (atrioventricular) block requiring permanent pacing at hospital discharge. Higher implantation and improvement of the devices were associated with decline of pace maker implantation rate over the years in experienced teams. While guidelines do not give definite recommendation regarding conductive disorder management and pacemaker indication, a strategy of selective telemetry monitoring (TM) after TAVR according to the risk of conductive disorders may be proposed to limit indication and lenght of stay of intensive care unit admission (ICU), allowing direct admission of lower risk patients in general cardiology ward (GCW) without TM, to decrease the duration of TM when a conductive disorder is stable or regressive and finally to decrease the rate of pacemakers implantation. Potential benefit may also include limitation of ICU overload in high volume TAVR centers, investigators can also expect shorter hospitalization duration, with potential economic impact, in line with the development of algorithms for fast track procedures. Therefore the main objective of our prospective study was to evaluate feasibility and safety of a strategy of management of conductive disorders after TAVR based on an algorithm of diagnosis, monitoring and therapeutic strategies based on ECG analysis.
Detailed Description
TAVR is now the reference method for the treatment of severe aortic stenosis in the elderly population. Regarding its good results, indications have recently been extended to younger, lower-risk patients. With the decrease in serious complications, severe conductive disorders requiring the implantation of a pacemaker have thus become the main complications of TAVR. Despite the experience of operators and modified implantation techniques and in absence of specific recommendations, the rate of pacemaker implantation after a TAVR procedure levels off between 10% and 20% regardless of the prosthesis used and with highly variable rates depending on the center. In the vast majoriy of cases, the conductive disorders only justify the monitoring of patients in ICU after the procedure, However, majority of conductive disorders will be regressive or stable and will not justify a permanent pacemaker implantation. Furthemore, this systematic monitoring contributes to unnecessarily overcrowding of these medical structures. Investigators thus put forward the hypothesis that by using a defined strategy for screening and monitoring conductive disorders occurring after a TAVR procedure, and by taking into account the recommendations on indication of definitive cardiac pacing, it would be possible to rationalize both the indications, the duration of monitoring (by telemetry/CICU or conventional sector) and the definitive pacemaker indication. Investigators thus hope, thanks to this rationalized strategy, to reduce the indications and durations of monitoring by telemetry or CICU after a TAVR and to shorten the durations of overall hospitalization, but also to reduce the indication for permanent cardiac pacing without risk for the patient.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Valvular Heart Disease
Keywords
Aortic Valve,, Aortic Valve Stenosis,, Heart Valve Prosthesis Implantation,, Transcatheter Aortic Valve Replacement,, Telemetry,, Intensive care

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
This is a non-comparative prospective interventional study, involving the human category, which aims to evaluate the efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR
Masking
None (Open Label)
Allocation
N/A
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Management of conductive disorders after TAVR
Arm Type
Other
Arm Description
Evaluation of efficacy and safety of a flowchart for screening, monitoring and management of conductive disorders after TAVR
Intervention Type
Other
Intervention Name(s)
Use of flowchart
Intervention Description
Use of flowchart for screening, monitoring and management of conductive disorders after TAVR
Primary Outcome Measure Information:
Title
Occurrence of a serious conductive disorder
Description
Occurrence of a serious conductive disorder (one among the following : syncope, malaise, sudden death, heart failure) outside the CICU (whether the patient was there admitted initially or not)
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Occurrence of a serious conductive disorder requiring specific management
Description
Occurrence of a serious conductive disorder requiring specific management (one among the following : drug treatment, need for a transient or permanent pacemaker), outside the CICU (whether the patient was there admitted initially or not)
Time Frame
Between inclusion and 1 month after TAVR procedure
Secondary Outcome Measure Information:
Title
Incidence and type of conductive disorders requiring transfer to CICU (cardiac intensive care unit)
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Pourcentage of Pacemaker implantation
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Time of onset of conductive disorders requiring a pacemaker (immediate, hospital phase, after discharge from hospital)
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Description of the evolution of conductive disorders that have not been the subject of pacemaker insertion (hospitalization)
Description
Number of conductive disorders that lead to patient's rehospitalization
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Description of the evolution of conductive disorders that have not been the subject of pacemaker insertion (death)
Description
Number of conductive disorders that lead to patient's death
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Death
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Clinical status at one month (NYHA (New York Heart Association)
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Death within the first month after TAVR
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Duration of hospitalization in CICU
Time Frame
Between inclusion and 1 month after TAVR procedure
Title
Duration of hospitalization in sector
Time Frame
Between inclusion and 1 month after TAVR procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Any patient who benefits from femoral TAVR regardless of the type of valve. Age ≥ 18 years old. Exclusion Criteria: Patients who require CICU monitoring for a reason other than conduction disorders Patients with pacemaker or defibrillator Pregnant or breastfeeding women Patient refusing or unable to give consent: patient under guardianship or curator, mentally retarded, dementia, language barrier Patient not affiliated with an SS scheme Patient under judicial protection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Florence LECLERCQ, MD
Phone
4 67 33 61 88
Ext
33
Email
f-leclercq@chu-montpellier.fr
Facility Information:
Facility Name
University Hospital
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florence LECLERCQ, MD
Phone
4 67 33 61 88
Ext
33
Email
f-leclercq@chu-montpellier.fr

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Evaluation and Validation of Management Strategy for Conductive Disorders After TAVR (EVATAVI)

We'll reach out to this number within 24 hrs